Therapeutic effect of colon tumor cells expressing FLT-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer

Cancer Immunology, Immunotherapy

Volumn 51, Issue 2, 2002, Pages 63-71

  Sivanandham, Muthukumaran ^a   Stavropoulos, Christos I ^a   Kim, Eugene M ^a   Mancke, Brian ^a   Wallack, Marc K ^a  

^a ST VINCENT S HOSPITAL   (United States)

Author keywords

CC 36 FL+systemic IL 2 therapy; Colon tumor cell; Survival

Indexed keywords

FLT3 LIGAND; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLON ADENOCARCINOMA; COLON TUMOR; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENE THERAPY; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 0036120658     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-001-0256-0     Document Type: Article

References (32)

1. Dendritic cells and the control of immunity
2. Synergistic action of Fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo
3. Flt3 ligand antitumor activity in a murine breast cancer model: A comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action
4. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer
5. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model
6. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer
7. The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells
8. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays with a note on carcinogenic structure
9. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma
10. Interleukin-2 production by tumor cells bypasses T helper function in the generation of antitumor response
11. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo
12. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of hematopoietic stem cells and is encoded by variant RNAs
13. Biological therapy with interleukin-2: Pre-clinical studies
14. Interleukin-2: Developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity
15. C-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities
16. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells
17. Flt3 ligand induces tumor regression and antitumor immune responses in vivo
18. Dramatic increase in the numbers of functionally mature dendritic cells in Flt-3 ligand-treated mice: Multiple dendritic cell subpopulations identified
19. Generating a T cell tumor-specific immune response in vivo: Can flt3-ligand-generated dendritic cells tip the balance?
20. + hematopoietic progenitor cells
21. FLT3-ligand administration inhibits liver metastases: Role of NK cells
22. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
23. + bone marrow
24. Characterization of tumorigenicity, mortality, metastasis, and splenomegaly of two cultured murine colon lines
25. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt-3 ligand: Implications for anti-cancer and antiviral therapy
26. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
27. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2
28. FLT3: Receptor and ligand. Biology and potential clinical application
29. FLT3 ligand induces the generation of functionally active dendritic cells in mice
30. Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2 gene encoded vaccinia virus studied in syngeneic CC-36 murine colon hepatic metastasis model
31. Both dendritic cells and monocytes induce autologous and allogeneic T cells receptive to interleukin 2
32. Antileukemic activity of Flt3 ligand in murine leukemia